PK / PD exposure-response planning
Frame the package around the first decision your team needs from the data.
Preclinical proof for GLP-1 receptor agonist
Build Semaglutide evidence before managing a lab.
VivoProof acts as a preclinical proof layer for drug builders. Start with a Semaglutide research question, then turn it into a scoped evidence plan for systems, samples, endpoints, data closeout, and feasibility review.
Research teams usually want to confirm whether a semaglutide lot, formulation, or comparator design can support metabolic efficacy, exposure-response, or tolerability decisions before a larger program.
Decision first
Start with the decision the data must support.
A useful request is not just a compound name. It names the decision, the system, the readouts, the reporting standard, and the constraints that could change feasibility.
Mouse metabolic efficacy screen
Map the system, comparator, sample schedule, and endpoint burden before review.
Tolerability and observation package
Decide whether the first pass needs exposure, tolerability, biomarkers, or tissue work.
Biomarker panel with raw endpoint exports
Specify the closeout standard so the raw tables and summary are useful after the run.
Evidence systems
Choose the smallest credible system for the question.
Many teams start by asking for animal testing. The right first package can also be a cell screen, dish assay, bioanalysis run, or tissue package when that is the smaller credible step.
Organism-level signal
Use when route, tolerability, exposure, metabolic, behavioral, or tissue-level questions cannot be answered in a dish.
Early signal before animals
Use when viability, pathway, direct-cell, or assay feasibility can reduce risk before an in vivo package.
Exposure and sample data
Use for LC-MS/MS, plasma exposure, sample handling, biomarker panels, or material-dependent readouts when available.
Local endpoint package
Use when tissue collection, necropsy, histology, imaging, or local-reaction review is part of the decision.
Inputs before scope
What a real Semaglutide request needs.
The Proof Planner can draft a useful starting point, but the formal review depends on material documents, assay availability, sample burden, and the closeout package your team needs.
Material and study inputs
- COA, purity, lot number, salt form, and storage temperature
- Available material quantity and proposed formulation or vehicle assumptions
- Comparator idea, model preference, and target decision from the data
Endpoint options
- Body weight, food intake, glucose, insulin, and lipid trends
- Plasma exposure or LC-MS/MS bioanalysis where feasible
- Clinical observations, chemistry panels, and final summary
What can change feasibility
Strain, diet model, route assumptions, sample volume, compound stability, and bioanalysis method availability drive feasibility and the final plan.
Output package
What your team gets back.
VivoProof coordinates the proof package and closeout so the output is useful for internal review, sponsor diligence, or the next experimental decision.
- Study assumption sheet and planned endpoint package
- Subject-level endpoint tables in XLSX/CSV
- English summary report with sample inventory and deviation notes
- Start with the Semaglutide question and available material context.
- Select the system, confidence level, sample map, and closeout format in Proof Planner.
- Complete contact and payment-method verification before exact estimate release.
- Feasibility, review path, and next action are confirmed online — no call required.
Public pages avoid protocols, dosing directions, treatment claims, and human-use instructions. Detailed plans are finalized only after research-use review, compound-document review, and facility review.
Next step
Design the Semaglutide evidence plan online.
Build a first-pass proof package for the research question, system, samples, closeout, and planning range. The formal scope is locked only after qualified review.